Ardelyx (ARDX) Jefferies London Healthcare Conference 2024 summary

Business overview and recent performance

• Two commercial drugs, Ibsrela for IBS-C and Xphozah for hyperphosphatemia, both addressing significant unmet needs.

• Ibsrela has been on the market for over two years, with 2024 revenue guidance set at $145–$150 million.

• Xphozah launched in late 2023, achieving over $130–$140 million in its first year.

• Expanded sales force in 2023 to increase reach and depth, targeting both GI and high-prescribing non-GI physicians.

• Sales force expansion completed in Q3, with full ramp-up expected to drive continued growth into 2025.

Reimbursement and regulatory environment

• Xphozah’s growth faces uncertainty due to potential inclusion in the Medicare bundle, which would impact reimbursement but not patient demand.

• Legislative efforts (the Patient Act) aim to delay bundling for two years, with strong support but pending Congressional approval.

• If included in the bundle, non-Medicare business remains robust, and patient access programs are in place to support those without coverage.

• Legal actions against CMS are ongoing, with plans to appeal recent dismissals and continue advocacy.

• Communication with physicians emphasizes continuity of care regardless of reimbursement changes.

Commercial strategy and market dynamics

• Focus on maintaining access for all patients, leveraging patient assistance programs and direct engagement with nephrologists.

• Physicians are well-informed about reimbursement changes and remain committed to prescribing based on patient need.

• Decision-making for Xphozah remains at the physician level, with minimal interference from dialysis organizations due to strategic choices around TDAPA.

• Sales force realignment has enabled deeper market penetration and more efficient territory coverage.

• Ongoing education and outreach to all provider sizes ensure consistent messaging and adoption.